Literature DB >> 12699394

Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.

Elisabeth Greiner1, Mariana Spetea, Roland Krassnig, Falko Schüllner, Mario Aceto, Louis S Harris, John R Traynor, James H Woods, Andrew Coop, Helmut Schmidhammer.   

Abstract

The synthesis, biological, and pharmacological evaluations of 14beta-O-phenylpropyl-substituted morphinan-6-ones are described. The most striking finding of this study was that all of the compounds from the novel series of differently N-substituted 14beta-O-phenylpropylmorphinans acted as powerful opioid agonists. Even with N-substituents such as cyclopropylmethyl and allyl, which are usually associated with distinct antagonist properties, only agonists were obtained. Compared to morphine, the N-cyclopropylmethyl derivative 15 showed considerably increased potency in the in vivo assays in mice (600-fold in the tail-flick assay, 60-fold in the paraphenylquinone writhing test, and 400-fold in the hot-plate assay). Remarkably, most of the new ligands were nonselective and exhibited binding affinities in the subnanomolar range at opioid receptors (mu, kappa, delta), with the N-propyl derivative 19 displaying the highest affinity for the mu-receptor (K(i) = 0.09 nM).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699394     DOI: 10.1021/jm021118o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Discovery of novel triazole-based opioid receptor antagonists.

Authors:  Qiang Zhang; Susan M Keenan; Youyi Peng; Anil C Nair; Seong Jae Yu; Richard D Howells; William J Welsh
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

2.  14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Authors:  Guo Li; Lindsey C K Aschenbach; Hengjun He; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-12-29       Impact factor: 2.823

3.  Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Authors:  Yunyun Yuan; Saheem A Zaidi; Orgil Elbegdorj; Lindsey C K Aschenbach; Guo Li; David L Stevens; Krista L Scoggins; William L Dewey; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2013-11-07       Impact factor: 7.446

4.  Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.

Authors:  Nick P R Nieland; Humphrey A Moynihan; Simon Carrington; Jillian Broadbear; James H Woods; John R Traynor; Stephen M Husbands; John W Lewis
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

Review 5.  Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.

Authors:  L Stavitskaya; A Coop
Journal:  Mini Rev Med Chem       Date:  2011-10       Impact factor: 3.862

6.  14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.

Authors:  Subramaniam Ananthan; Surendra K Saini; Christina M Dersch; Heng Xu; Nicholas McGlinchey; Denise Giuvelis; Edward J Bilsky; Richard B Rothman
Journal:  J Med Chem       Date:  2012-09-27       Impact factor: 7.446

7.  Probes for narcotic receptor mediated phenomena. 40. N-substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-ols.

Authors:  Malliga R Iyer; Yong Sok Lee; Jeffrey R Deschamps; Richard B Rothman; Christina M Dersch; Arthur E Jacobson; Kenner C Rice
Journal:  Bioorg Med Chem       Date:  2009-11-18       Impact factor: 3.641

8.  In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function.

Authors:  Mariana Spetea; Catalina R Bohotin; Muhammad F Asim; Kurt Stübegger; Helmut Schmidhammer
Journal:  Eur J Pharm Sci       Date:  2010-06-18       Impact factor: 4.384

9.  Insights into subtype selectivity of opioid agonists by ligand-based and structure-based methods.

Authors:  Jianxin Cheng; Guixia Liu; Jing Zhang; Zhejun Xu; Yun Tang
Journal:  J Mol Model       Date:  2010-05-25       Impact factor: 1.810

10.  Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.

Authors:  Gerta Cami-Kobeci; Adrian P Neal; Faye A Bradbury; Lauren C Purington; Mario D Aceto; Louis S Harris; John W Lewis; John R Traynor; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.